David Gill, CFO of EndoChoice, has been appointed to the board of directors and chairman of the audit committee of regenerative medicine company Histogenics.
"We are extremely pleased to welcome David to the Histogenics' Board of Directors," said Adam Gridley, president and CEO of Histogenics. "David's financial and industry expertise and experience make him an excellent choice for Histogenics as both a board member and Chairman of the Audit Committee."
Mr. Gill joined EndoChoice as CFO in 2014. He has held the CFO position with a number of other organizations including INC Research and TransEnterix.
Histogenics focuses on regenerative medicine in the musculoskeletal marketplace.